Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
CARMIEL, Israel, May 25, 2017 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that Moshe Manor, the Company's President and Chief Executive Officer, will present a corporate overview at the Jefferies 2017 Global Healthcare Conference on June 7 at 9:00 a.m. ET. The conference is being held at the Grand Hyatt Hotel in New York City.
A live and archived webcast of the presentation will be available at www.protalix.com, on the event calendar page.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others.
Investor Contact Marcy Nanus The Trout Group, LLC 646-378-2927 [email protected]
